🔎 Trials Near Me

Início › Leucemia Mieloide Aguda › Utah

Ensaios clínicos de Leucemia Mieloide Aguda em Utah

17 estudos para Leucemia Mieloide Aguda estão buscando participantes em locais em Utah.

Cidades em Utah

Texto oficial do estudo (Inglês)

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Huntsman Cancer Institute/University of Utah, Salt Lake City
RecrutandoFase 2
Idades de 18 a 59 · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • Intermountain Healthcare LDS Hospital, Salt Lake City
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Huntsman Cancer Institute/University of Utah, Salt Lake City
  • George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Huntsman Cancer Institute/University of Utah, Salt Lake City
  • George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • Huntsman Cancer Institute/University of Utah, Salt Lake City
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Huntsman Cancer Institute/University of Utah, Salt Lake City
RecrutandoFase 2
Idades de 18 a 59 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Primary Children's Hospital, Salt Lake City
RecrutandoFase 3
6 Months – 21 Years · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT04293562

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • Huntsman Cancer Institute, Salt Lake City
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT06824168

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

  • Huntsman Cancer Institute - University of Utah Health, Salt Lake City
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT04996875

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

  • Huntsman Cancer Institute/University of Utah, Salt Lake City
RecrutandoFase 1
Idades de 18 a 75 · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT05886049

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • Primary Children's Hospital, Salt Lake City
RecrutandoFase 3
29 Days – 21 Years · Todos os sexos · Atualizado em 24 de ago. de 2026 · NCT05183035

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • University of Utah, Salt Lake City
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 6 de jul. de 2026 · NCT01351545

Ivosidenib as Post-HSCT Maintenance for AML

  • Huntsman Cancer Institute, University of Utah, Salt Lake City
RecrutandoFase 2
Idades de 18 a 75 · Todos os sexos · Atualizado em 18 de jun. de 2026 · NCT06707493

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

  • University of Utah, Salt Lake City
RecrutandoFase 1
Idades 13 e acima · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT04771572

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

  • University of Utah, Salt Lake City
RecrutandoFase 1
Até 21 anos · Todos os sexos · Atualizado em 22 de abr. de 2026 · NCT05101551

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • Huntsman Cancer Institute, Salt Lake City
  • Intermountain Healthcare, Salt Lake City
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 24 de mar. de 2026 · NCT04988555

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.